Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Feb;8(1):9-13.
doi: 10.5582/irdr.2019.01016.

Management strategies in facioscapulohumeral muscular dystrophy

Junren Lu  1 , Zhenjun Yao  1 , Yi Yang  1 , Chi Zhang  1 , Jian Zhang  1 , Ying Zhang  2
Affiliations
Review

Management strategies in facioscapulohumeral muscular dystrophy

Junren Lu et al. Intractable Rare Dis Res. 2019 Feb.

Abstract

Facioscapulohumeral muscular dystrophy (FSHD) also known as Landouzy-Dejerine disease, is an autosomal-dominant disorder of the skeletal muscles with the name according to the various muscle groups it affects: the face, shoulders and upper arms. It is the third most common genetic degenerative disorder of the skeletal muscles without specific patterns in all the affected individuals. At present there is no cure for the disease but numerous management strategies are available to improve the quality of life and prevent further degeneration of various muscle groups. This review aims to provide an insight on the management strategies for FSHD patients including both lifestyle and medical intervention.

Keywords: Facioscapulohumeral muscular dystrophy; Landouzy-Dejerine disease; clinical manifestations; management; surgical intervention.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Schematic representation of a pathologic Chromosome 4 in FSHD Type 1 compared to a normal allele.The normal allele normally has 11-100 repeats of D4Z4 (represented by ovals) which is contracted to less than 10 units in FSHD Type 1. In FSHD Type II there is no evidence of pathological change of D4Z4 but there is hypomethylation loss in chromosome 4 and 10.
See this image and copyright information in PMC

References

    1. Tawil R, Van Der Maarel SM. Facioscapulohumeral muscular dystrophy. Muscle Nerve. 2006; 34:1-15. - PubMed
    1. Kilmer DD, Abresch RT, McCrory MA, Carter GT, Fowler WM Jr, Johnson ER, McDonald CM. Profiles of neuromuscular diseases. Facioscapulohumeral muscular dystrophy. Am J Phys Med Rehabil. 1995; 74:S131-S139. - PubMed
    1. Sposito R, Pasquali L, Galluzzi F, Rocchi A, Solito B, Soragna D, Tupler R, Siciliano G. Facioscapulohumeral muscular dystrophy type 1A in northwestern Tuscany: A molecular genetics-based epidemiological and genotype-phenotype study. Genet Test. 2005; 9:30-36. - PubMed
    1. Deenen JC, Arnts H, van der Maarel SM, Padberg GW, Verschuuren JJ, Bakker E, Weinreich SS, Verbeek AL, van Engelen BG. Population-based incidence and prevalence of facioscapulohumeral dystrophy. Neurology. 2014; 83:1056-1059. - PMC - PubMed
    1. Deenen JC, Horlings CG, Verschuuren JJ, Verbeek AL, van Engelen BG. The epidemiology of neuromuscular disorders: A comprehensive overview of the literature. J Neuromuscul Dis. 2015; 2:73-85. - PubMed